Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)

An expert discusses updated overall survival results from the phase 2 PHAROS study evaluating encorafenib plus binimetinib in patients with BRAF V600E–mutant metastatic non–small cell lung cancer (mNSCLC).